Unopposed Estrogen in Leiomyosarcoma: Safety Considerations

Hormonal Sensitivity of Leiomyosarcoma

Approximately 50% of uterine leiomyosarcomas express estrogen and/or progesterone receptors, making them potentially hormone-sensitive 2
Hormone replacement therapy (HRT) containing estrogens is specifically contraindicated in patients with endometrial stromal sarcomas and should be avoided in leiomyosarcoma 1, 3
Current evidence suggests that unopposed estrogen may increase the risk of tumor growth in hormone receptor-positive leiomyosarcomas 4, 5

Studies have shown that current estrogen-only users had a 6-fold increased risk of uterine leiomyomata requiring hospitalization compared to never users, suggesting potential growth-promoting effects 4

For patients with leiomyosarcoma requiring hormonal management, consider progestins without estrogen for symptomatic management when necessary 1
GnRH analogues may be considered for pre-menopausal patients requiring hormonal suppression 1

For patients requiring management of menopausal symptoms, non-hormonal approaches should be first-line therapy 2
If hormonal therapy is absolutely necessary, consider progestin-only options 1